Business Wire

Ecron Acunova to offer end-to-end capabilities as ‘Navitas Life Sciences’

9.6.2017 18:00 | Business Wire

Jaa

Ecron Acunova (EA), a fully owned subsidiary of TAKE Solutions and a globally recognized full service CRO with Clinical and BA/BE expertise, announced that it would be consolidating its capabilities with TAKE’s niche Life Sciences brand Navitas and Intelent to form a unified go-to-market entity – Navitas Life Sciences.

EA’s significant Clinical capabilities, having conducted over 1300 studies including BA/BE, NIS, and phase II – IV in its state-of-the-art and audited facilities, will be augmented by legacy brands Navitas’s technology led solutions across Clinical, Regulatory and Safety, and Intelent’s big data and analytics expertise to form the 360 degree service provider Navitas Life Sciences. The unified Navitas Life Sciences will serve as an end-to-end strategic partner for Life Sciences companies to help them address their critical challenges and achieve their desired outcomes.

Marty Boom, Managing Director, Ecron Acunova, said, “Capitalizing on the phenomenal growth opportunities in the Life Sciences industry calls for diverse capabilities. The unification of Ecron Acunova, Navitas and Intelent will enable a seamless consolidation of capabilities in the form of Navitas Life Sciences, which will enable us to offer clients a full-service coverage of the Pharma and Biotech R&D market.”

Ram Yeleswarapu, President & CEO, TAKE Solutions, said,We are proud to bring together our substantial and niche capabilities under the unified ambit of Navitas Life Sciences to present our client with truly transformational, flexible and adaptable end-to-end offerings. In addition to our technology driven offerings and insights derived from our world-class proprietary industry networks, our clients now also be able to benefit from the consolidated brand’s proven clinical capabilities and trial experiences.”

About Navitas Life Sciences

Navitas Life Sciences, a wholly owned subsidiary of TAKE Solutions, works as a strategic partner for large and mid-sized Life Sciences organizations to address critical challenges and achieve desired outcomes in Clinical, Regulatory and Safety. Navitas’ technology-led Life Sciences services are augmented with the full-service CRO with Clinical & BA/BE capabilities, and Life Sciences data analytics expertise of legacy brands Ecron Acunova and Intelent to deliver flexible, scalable and innovative solutions for its global clients.

Navitas Life Sciences’ expertise spans more than 1300 studies including BA/BE, NIS, and phase II – IV, and 70,000 regulatory submissions. The company’s unique proprietary network forums that include 300+ professionals from 100+ life sciences companies generate insights that help members prepare for the future of the industry. Navitas Life Sciences seamlessly combining best-in-class processes, meaningful and unique industry insight, innovative technology, exacting analytics and a customer-centric culture. For more information, visit www.navitaslifesciences.com

About TAKE Solutions

TAKE Solutions is a globally recognized knowledge intensive player, delivering comprehensive and niche solutions in Life Sciences (LS). TAKE offers IP-based software and extensive knowledge-based solutions to enable efficient Clinical, Regulatory, Safety outcomes for global clients. TAKE encompasses specialized capabilities under its Life Sciences business Navitas, whose technology-led Life Sciences services across Clinical, Regulatory and Safety are augmented by full-service CRO with Clinical & BA/BE capabilities and Big Data analytics expertise of its legacy brands Ecron Acunova and Intelent. Navitas Life Sciences delivers flexible and scalable solutions by seamlessly combining best-in-class processes, meaningful and unique industry insight, innovative technology, exacting analytics and a customer-centric culture.

TAKE’s significant recognitions include a patent win from the United States Patent and Trademark Office (USPTO) for its ‘Method for Optimizing Clinical Data Standardization’, a ‘Leader’ certification in Drug Safety Services & Life Sciences R&D IT Outsourcing from IDC, recognition as the ‘Dream Employer of the Year’ at the World HRD Congress, the title of ‘Most Admired Brand –IT’ from the Asian Customer Engagement Forum and a Special Commendation for excellence in Corporate Governance from the Golden Peacock Awards. With its global headquarters in Chennai, India, TAKE has a proven track record of delivering world-class solutions to more than 400 customers worldwide, including 9 of the top 10 global Pharma companies. For more information, please visit www.takesolutions.com.

Contact information

Navitas Life Sciences
Birgit Mund
+49 69 6680 300
birgit.mund@navitaslifesciences.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

IFF to Present at the Barclays Global Consumer Staples Conference21.8.2017 23:15Tiedote

Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, today announced that Andreas Fibig, Chairman and Chief Executive Officer will present at the Barclays Global Consumer Staples Conference in Boston, MA on Thursday, September 7, 2017 at 11:15 a.m. EDT. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for explorati

Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform21.8.2017 23:11Tiedote

Celularity, Inc., a newly formed biotechnology company, today announced its acceleration of cell and tissue regenerative therapies to address unmet medical needs in cancer and chronic and degenerative disease. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors. Celularity has been created through the contributions of extensive intellectual property, clinical-stage assets, basic and clinical research, and development expertise including: Several clinical-stage immuno-oncology and regenerative medicine assets and a pipeline of pre-clinical assets Proprietary allogeneic (“readily accessible”) immunotherapy platform 200+ issued and pending patents in cell therapy

European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 16:25Tiedote

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the

IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 15:00Tiedote

IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman

PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 11:03Tiedote

PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate

Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 11:00Tiedote

Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme